ASCO 2017: Impact of MET Inhibitors on Survival in Non–Small Cell Lung Cancer
Treatment with a MET tyrosine kinase inhibitor was associated with improvement in overall survival in patients with MET exon 14–mutant (METdel14) non–small cell lung cancer (NSCLC), according to research presented by Mark M. Awad, MD, PhD, of the Dana-Farber Cancer Institute, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8511).
Dr. Awad and colleagues conducted a multicenter retrospective analysis of 148 patients with METdel14 NSCLC to determine whether treatment with MET inhibitors had an impact on survival. Of the 34 patients with metastatic disease who had never received a MET inhibitor, the median overall survival was 8.1 months, compared with 24.6 months in the 27 patients with metastatic disease who had received at least one MET inhibitor (including crizotinib, glesatinib, capmatinib, and ABBV-399).
“The prognosis of patients who never received treatment with a MET inhibitor appears to be poor, particularly among METdel14 cancers with concurrent MET amplification,” the investigators revealed.
Based on these results, the investigators suggest that testing for MET exon 14 mutations should be performed upfront in all patients with stage IV NSCLC and prompt initiation of a MET inhibitor should be considered in patients with METdel14 NSCLC.